Cytek Biosciences (CTKB) EBITDA (2020 - 2026)

Cytek Biosciences has reported EBITDA for 7 years, with the latest figure at -$18.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 55.81% year-over-year to -$18.7 million; the trailing twelve-month figure through Mar 2026 stood at -$71.0 million (down 589.04% YoY), and the FY2025 full-year result was -$64.3 million, down 1259.7% from the prior year.
• EBITDA for Q1 2026 stood at -$18.7 million, up from -$42.7 million in the prior quarter.
• The five-year high for EBITDA was $9.6 million in Q4 2024, with the low at -$42.7 million in Q4 2025.
• Historically, EBITDA has averaged -$5.8 million across 5 years, with a median of -$5.0 million in 2025.
• Annual changes were most pronounced in 2022 — EBITDA surged 169.63% — and 2023, when it tumbled 823.04%.
• Cytek Biosciences' EBITDA stood at $3.6 million in 2022, then jumped by 63.53% to $5.8 million in 2023, then jumped by 64.58% to $9.6 million in 2024, then sank by 546.32% to -$42.7 million in 2025, then jumped by 56.07% to -$18.7 million in 2026.
• The last three EBITDA figures came in at -$18.7 million (Q1 2026), -$42.7 million (Q4 2025), and -$4.6 million (Q3 2025), per Business Quant data.